Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma

Journal of Thoracic Oncology - Tập 7 - Trang 1184-1191 - 2012
Michaela B. Kirschner1, Yuen Yee Cheng1, Bahareh Badrian2, Steven C. Kao1,3, Jenette Creaney4,5, J James B. Edelman6, Nicola J. Armstrong7, Michael P. Vallely6, Arthur W. Musk4,8, Bruce W.S. Robinson4,5, Brian C. McCaughan6, Sonja Klebe9, Steven E. Mutsaers2, Nico van Zandwijk1, Glen Reid1
1Asbestos Diseases Research Institute (ADRI), Bernie Banton Centre, University of Sydney, New South Wales, Australia
2Lung Institute of Western Australia, Centre for Asthma, Allergy, and Respiratory Research and Pathwest Laboratories of Medicine, University of Western Australia, Perth, Australia
3Department of Medical Oncology, Concord Hospital, Sydney, Australia
4National Research Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
5Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Western Australia, Australia
6Cardiothoracic Surgical Unit, Royal Prince Alfred Hospital; The Baird Institute and Faculty of Medicine, University of Sydney, Australia
7Cancer Research Program, Garvan Institute for Medical Research and School of Mathematics and Statistics, University of New South Wales, Sydney, Australia
8Department of Population Health, University of Western Australia, Western Australia, Australia
9Department of Anatomical Pathology, Flinders Medical Centre, Adelaide, Australia

Tài liệu tham khảo

Rake, 2009, Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study, Br J Cancer, 100, 1175, 10.1038/sj.bjc.6604879 Ramazzini, 1999, Call for an international ban on asbestos, J Occup Environ Med, 41, 830, 10.1097/00043764-199910000-00003 Hasegawa, 2008, Malignant mesothelioma: current status and perspective in Japan and the world, Gen Thorac Cardiovasc Surg, 56, 317, 10.1007/s11748-007-0243-2 Stahel, 2010, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v126, 10.1093/annonc/mdq173 Creaney, 2008, Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma, J Thorac Oncol, 3, 851, 10.1097/JTO.0b013e318180477b Park, 2008, Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study, Am J Respir Crit Care Med, 178, 832, 10.1164/rccm.200802-258OC Pass, 2005, Asbestos exposure, pleural mesothelioma, and serum osteopontin levels, N Engl J Med, 353, 1564, 10.1056/NEJMoa051185 Robinson, 2003, Mesothelin-family proteins and diagnosis of mesothelioma, Lancet, 362, 1612, 10.1016/S0140-6736(03)14794-0 Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res, 18, 997, 10.1038/cr.2008.282 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci USA, 105, 10513, 10.1073/pnas.0804549105 Lawrie, 2008, Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, Br J Haematol, 141, 672, 10.1111/j.1365-2141.2008.07077.x Resnick, 2009, The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform, Gynecol Oncol, 112, 55, 10.1016/j.ygyno.2008.08.036 Huang, 2010, Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer, Int J Cancer, 127, 118, 10.1002/ijc.25007 Ng, 2009, Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening, Gut, 58, 1375, 10.1136/gut.2008.167817 Reid, 2011, Circulating microRNAs: Association with disease and potential use as biomarkers, Crit Rev Oncol Hematol, 80, 193, 10.1016/j.critrevonc.2010.11.004 Kirschner, 2011, Haemolysis during sample preparation alters microRNA content of plasma, PLoS ONE, 6, e24145, 10.1371/journal.pone.0024145 Kao, 2011, Validation of tissue microarray technology in malignant pleural mesothelioma, Pathology, 43, 128, 10.1097/PAT.0b013e328342016c Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25, 402, 10.1006/meth.2001.1262 Hunter, 2008, Detection of microRNA expression in human peripheral blood microvesicles, PLoS ONE, 3, e3694, 10.1371/journal.pone.0003694 Tanaka, 2009, Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients, PLoS ONE, 4, e5532, 10.1371/journal.pone.0005532 Balatti, 2011, MicroRNAs dysregulation in human malignant pleural mesothelioma, J Thorac Oncol, 6, 844, 10.1097/JTO.0b013e31820db125 Benjamin, 2010, A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma, J Mol Diagn, 12, 771, 10.2353/jmoldx.2010.090169 Busacca, 2010, MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications, Am J Respir Cell Mol Biol, 42, 312, 10.1165/rcmb.2009-0060OC Gee, 2010, Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma, Int J Cancer, 127, 2859, 10.1002/ijc.25285 Guled, 2009, CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, 48, 615, 10.1002/gcc.20669 Ivanov, 2010, Pro-tumorigenic effects of miR-31 loss in mesothelioma, J Biol Chem, 285, 22809, 10.1074/jbc.M110.100354 Pass, 2010, hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma, Cancer Res, 70, 1916, 10.1158/0008-5472.CAN-09-3993 Santarelli, 2011, Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma, PLoS ONE, 6, e18232, 10.1371/journal.pone.0018232 LaDou, 2010, The case for a global ban on asbestos, Environ Health Perspect, 118, 897, 10.1289/ehp.1002285 Olsen, 2011, Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation, Med J Aust, 195, 271, 10.5694/mja11.10125 Ohyashiki, 2011, Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma, PLoS ONE, 6, e16408, 10.1371/journal.pone.0016408 Shigoka, 2010, Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development, Pathol Int, 60, 351, 10.1111/j.1440-1827.2010.02526.x Fichtlscherer, 2010, Circulating microRNAs in patients with coronary artery disease, Circ Res, 107, 677, 10.1161/CIRCRESAHA.109.215566 Vasilescu, 2009, MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis, PLoS ONE, 4, e7405, 10.1371/journal.pone.0007405 Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ Res, 107, 810, 10.1161/CIRCRESAHA.110.226357 Diamandis, 2010, Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst, 102, 1462 Kulasingam, 2008, Strategies for discovering novel cancer biomarkers through utilization of emerging technologies, Nat Clin Pract Oncol, 5, 588, 10.1038/ncponc1187 Cheng, 1994, p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma, Cancer Res, 54, 5547 Landgraf, 2007, A mammalian microRNA expression atlas based on small RNA library sequencing, Cell, 129, 1401, 10.1016/j.cell.2007.04.040
Thông tin
Thông tin xuất bản

Journal of Thoracic Oncology

Tập 7

1184-1191

Thông tin tác giả